Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: An open study of dose reduction for chronic schizophrenia

International Clinical Psychopharmacology

Volumn 18, Issue 6, 2003, Pages 323-329

  Suzuki, Takefumi ^a   Uchida, Hiroyuki ^a   Tanaka, Kenji F ^a   Tomita, Masayuki ^a   Tsunoda, Kenichi ^a   Nomura, Kensuke ^a   Takano, Harumasa ^a   Tanabe, Akira ^a   Watanabe, Koichiro ^a   Yagi, Gohei ^a   Kashima, Haruo ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Antipsychotics; Dose reduction; High dose therapy; Polypharmacy; Schizophrenia

Indexed keywords

BROMPERIDOL; CHLORPROMAZINE; CLOCAPRAMINE; CLOSPIPRAMINE; EMONAPRIDE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OXYPERTINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; RISPERIDONE; SULPIRIDE; SULTOPRIDE; THIORIDAZINE; TIMIPERONE; ZOTEPINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG POTENCY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MALE; MENTAL PATIENT; POLYPHARMACY; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 10744227290     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200311000-00003     Document Type: Article

References (37)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). Washington, DC: American Psychiatric Association.
2. American Psychiatric Association (1997). Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 154 (suppl 4):1-63.
3. Ayd FJ Jr (1955). Large doses of chlorpromazine in the treatment of psychiatric patients. Dis Nerv Syst 16:146-149.
4. Baldessarini RJ, Cohen BM, Teicher MH (1988). Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis. Arch Gen Psychiatry 45:79-91.
5. Carpenter WT, Buchanan RW, Kirkpatrick B, Lann HD, Breier AF, Summerfelt AT (1999). Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiatry 156:412-418.
6. Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002). Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28: 75-84.
7. Freudenreich O, Goff DC (2002). Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 106:323-330.
8. Guy W (1976). ECDEU Assessment Manual For Psychopharmacology. Washington DC: Department of Health, Education and Welfare, pp. 217-222.
9. Hirschowitz J, Hitzemann R, Piscani K, Burr G, Frecska E, Culiton D, et al. (1997). The dose reduction in schizophrenia (DORIS) study: a final report. Schizophr Res 23:31-43.
10. Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, et al. (1988). Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Arch Gen Psychiatry 45:797-805.
11. Inagaki A, Inada T, Fujii Y, Yagi G, Yoshio T, Nakamura H, Yamauchi K (1999). [Not available in English]. Tokyo: Seiwa Press.
12. Inagaki A, Fuwano S, Fukuda M, Kumada Y, for the JESS Study Group (2001). Prescription pattern of antipsychotic in schizophrenic inpatients treated in the national mental hospitals in Japan. Presented at the 2001 Collegium Internationale Neuro-Psychopharmacologicum (CINP) Regional Meeting; Hiroshima, Japan; English Abstract, pp. 21.
13. Inderbitzin LB, Lewine RRJ, Schller-Gilkey G, Swofford CD, Egan GJ, Gloersen BA, et al. (1994). A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. Am J Psychiatry 151:1753-1759.
14. Ito C, Kubota Y, Sato M (1999). A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatr Clin Neurosci 53 (suppl.):S35-S40.
15. Kane J, Honigfeld G, Singer J, Melzer H, for the Clozaril Collaborative Study Group (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with colorpromazine. Arch Gen Psychiatry 45:789-796.
16. Latimer PR (1995). Tardive dyskinesia: a review. Can J Psychiatry 40 (suppl 2):S49-S54.
17. Lehman AF, Steinwachs DM, for the coinvestigators of the PORT project (1998). Translating research into practice: the schizophrenia patient outcome research team (PORT) treatment recommendations. Schizophr Bull 24:1-10.
18. Leslie DL, Rosenheck RA (2001). Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system. Individual and facility predictors. Med Care 39:923-933.
19. Leslie DL, Rosenheck RA (2002). From conventional to atypical antipsychotics and back; dynamic processes in the diffusion of new medications. Am J Psychiatry 159:1534-1540.
20. Lieberman RP, Putten TV, Marshall BD Jr, Mintz J, Bowen L, Kuehnel TG, et al. (1994). Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. Am J Psychiatry 151:756-759.
21. McClelland HA, Farquharson RG, Leyburn P, Furness JA, Schiff AA (1976). Very high dose fluphenazine decanoate. Arch Gen Psychiatry 33: 1435-1439.
22. McEvoy JP, Hogarty GE, Steingard S (1991). Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48:739-745.
23. Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP (1999). The texas medication algorithm project (TMAP) schizophrenia algorithms. J Clin Psychiatry 60:649-657.
24. Prien RF, Cole JO (1968). High dose chlorpromazine therapy in chronic schizophrenia. Report of National Health Institute of Mental Health-Psychopharmacotherapy Research Branch Collaborative Study Group. Arch Gen Psychiatry 18:482-495.
25. Prien RF, Levine J, Cole JO (1969). High dose trifluoperazine therapy in chronic schizophrenia. Am J Psychiatry 126:305-313.
26. Putten TV, Marder SR, Mintz J (1990). A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 47:754-758.
27. Reardon GT, Rifkin A, Schwartz A, Meyerson A, Siris SH (1989). Changing pattern of neuroleptic dosage over a decade. Am J Psychiatry 146:726-729.
28. Rifkin A, Doddi S, Karajgi B, Borenstein M, Wachspress M (1991). Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 48:166-170.
29. Sernyak MJ, Leslie D, Rosenheck R (2003). Use of system-wide outcome monitoring data to compare the effectiveness of atypical neuroleptic medications. Am J Psychiatry 160:310-315.
30. Smith RC (1994). Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients. Arch Gen Psychiatry 51:427-429.
31. Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M (1997). Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 54:49-55.
32. Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, et al. (1992). Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 49:354-361.
33. Volavka J, Cooper TB, Czobor P, Meisner M (1995). Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 52:837-845.
34. Volavka J, Cooper TB, Czobor P, Lindenmayer J-P, Citrome LL, Mohr P, Bark N (2000). High-dose treatment with haloperidol: the effect of dose reduction. J Clin Psychopharmacol 20:252-256.
35. Wahlbeck K, Cheine M, Essali A, Adams C (1999). Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 156:990-999.
36. Weiden PJ, Aquila R, Dalheim L, Standard JM (1997). Switching antipsychotic medications. J Clin Psychiatry 58 (suppl 10):63-72.
37. Yamauchi K, Baba K, Ikegami N, Miyaoka H, Kamijima K (1998). A survey of drug utilization in psychiatric hospitals in Japan: The basic analysis of the current status of prescription patterns [in Japanese]. Psychiatr Neurol Jap 100:51-67.